LONDON (Alliance News) - Scancell Holdings PLC on Tuesday noted a paper has been published in the Cancer Research journal outlining the rationale behind the firm's Moditope platform and the experimental results supporting the system.
"The publication of this paper on the science behind Moditope in such a prestigious and widely read cancer journal is not only a great achievement for the research team at Scancell, it provides a ringing endorsement from the scientific community for this completely innovative approach to the treatment of cancer," said Lindy Durrant, Scancell's joint chief executive.
Scancell added Modi-1, the lead product from its Moditope platform, is progressing through pre-clinical development in treating triple negative breast cancer and ovarian cancer patients.
Scancell shares were up 7.7% to 21.40 pence early Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)